Use of Angiotensin II in Severe Vasoplegia After Left Pneumonectomy Requiring Cardiopulmonary Bypass: A Renin Response Analysis.


Journal

Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501

Informations de publication

Date de publication:
10 2020
Historique:
entrez: 15 9 2020
pubmed: 16 9 2020
medline: 26 5 2021
Statut: ppublish

Résumé

Describe a case of post-pneumonectomy vasoplegia managed with angiotensin II. Plasma renin activity was measured at specific time intervals to describe the relationship between endogenous renin activity and exogenous angiotensin II supplementation. Case report. Spectrum Health Cardiothoracic Critical Care Unit. Fifty-seven-year-old male. None. Plasma renin activity at five pre-determined time points. Angiotensin II caused a significant increase in mean arterial pressure and a rapid reduction in catecholamine vasopressor doses from 0.75 to 0.31 mcg/kg/min norepinephrine equivalents. Plasma renin activity drawn immediately before angiotensin II initiation was 40 ng/mL/hr (normal, 0.6-3.0 ng/mL/hr) with resultant drop to 22 and 12 ng/mL/hr at 2 and 6 hours after angiotensin II initiation, respectively. The patient suffered no end-organ damage and achieved a positive outcome, discharging home on postoperative day 11. Exogenous angiotensin II reduced catecholamine vasopressor doses and had an apparent effect in reducing endogenous renin production in this case. Prospective research is warranted to determine the utility of angiotensin II and to better understand it effects on the dysfunctional renin-angiotensin-aldosterone system during vasoplegic shock.

Identifiants

pubmed: 32931196
doi: 10.1097/CCM.0000000000004502
pii: 00003246-202010000-00035
doi:

Substances chimiques

Vasoconstrictor Agents 0
Angiotensin II 11128-99-7
Renin EC 3.4.23.15

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e912-e915

Références

Levy B, Fritz C, Tacon E, et al. Vasoplegia treatments: The past, the present and the future. CCM Rev 2018; 22:52
Asleh R, Alnsasra H, Daly RC, et al. Predictors and clinical outcomes of vasoplegia in patients bridged to heart transplantation with continuous-flow left ventricular assist devices. J Am Heart Assoc 2019; 8:e013108
Khanna A, English SW, Wang XS, et al.; ATHOS-3 Investigators: Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 2017; 377:419–430
Giapreza (Angiotensin II) [Prescribing Information]. 2018San Diego, CA, La Jolla Pharmaceutical Company.
Ostermann M, Boldt D, Harper M, et al. Angiotensin in ECMO patients with refractory shock. Crit Care 2018; 22:228
Evans A, McCurdy MT, Weiner M, et al. Use of angiotensin II for post cardiopulmonary bypass vasoplegic syndrome. Ann Thorac Surg 2019; 108:e5–e7
Wieruszewski PM, Radosevich MA, Kashani KB, et al. Synthetic human angiotensin II for postcardiopulmonary bypass vasoplegic shock. J Cardiothorac Vasc Anesth 2019; 33:3080–3084
Wieruszewski PM, Sims CR, Daly RC, et al. Use of angiotensin II for vasoplegic shock in a combined heart and liver transplant recipient with systolic anterior motion physiology. J Cardiothorac Vasc Anesth 2019; 33:2366–2367
Chawla LS, Chen S, Bellomo R, et al. Angiotensin converting enzyme defects in shock: Implications for future therapy. Crit Care 2018; 22:274
Bellomo R, Wunderink RG, Szerlip H, et al. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit Care 2020; 24:43
Bussard RL, Busse LW. Angiotensin II: A new therapeutic option for vasodilatory shock. Ther Clin Risk Manag 2018; 14:1287–1298
Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: Pathophysiology and therapy. Circ Res 2013; 113:739–753
Gleeson PJ, Crippa IA, Mongkolpun W, et al. Renin as a marker of tissue-perfusion and prognosis in critically ill patients. Crit Care Med 2019; 47:152–158
Barbieri A, Giuliani E, Marchetti G, et al. Plasma renin concentration as a predictor of outcome in a medical intensive care setting: A retrospective pilot study. Minerva Anestesiol 2012; 78:1248–1253
Chung KS, Song JH, Jung WJ, et al. Implications of plasma renin activity and plasma aldosterone concentration in critically ill patients with septic shock. Korean J Crit Care Med 2017; 32:142–153
du Cheyron D, Lesage A, Daubin C, et al. Hyperreninemic hypoaldosteronism: A possible etiological factor of septic shock-induced acute renal failure. Intensive Care Med 2003; 29:1703–1709
du Cheyron D, Bouchet B, Cauquelin B, et al. Hyperreninemic hypoaldosteronism syndrome, plasma concentrations of interleukin-6 and outcome in critically ill patients with liver cirrhosis. Intensive Care Med 2008; 34:116–124

Auteurs

Brian Trethowan (B)

Department of Cardiac Anesthesia, Grand Rapids, MI.

Christopher J Michaud (CJ)

Department of Pharmacy, Spectrum Health, Grand Rapids, MI.

Sarah Fifer (S)

Spectrum Health Medical Group, Grand Rapids, MI.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH